Entheogen Biotech is a Canadian controlled corporation constituted in 2021. Our mission is to supply natural psychedelic compounds to worldwide clinical studies which are currently and almost exclusively using synthetic compounds, and to support the advancement of clinical research in mental health for institutions primarily seeking traditional regulatory-approval pathways for psychedelics including psilocybin and psilocin. 

​

Our unparalleled (patent pending) cultivation technique is transformational and positions us to be the only/leading supplier of natural psilocybin and psilocin compounds in scale and consistent potency from our euGMP laboratory located in Jamaica.  Entheogen is a Canadian controlled corporation constituted in 2021.

​

Entheogen launched its Jamaican laboratory in 2018 which operates under euGMP standards. Our team of PhDs utilized patent pending cultivation techniques in the development of industry leading intensive breeding and library of 75+ fungi compounds with proprietary genome biomarkers, in the cultivation of natural psilocibin and psilocin from mycelium, including our ongoing research with non-psychoactive compounds.

 

Our publications on our proprietary techniques were conducted with the service, validation and collaboration of the University of Athens. Our body of work includes presentations at international conference such as the psychedelics conference at the Society for Medicinal Plant and Natural Product Research in Greece.

 

The team has further developed expertise in compound extraction and purification analytics and testing and have advanced Entheogen’s ability to improve clinical studies and API standards using organic or natural compounds, unlike most studies which currently utilize synthetic compounds. 

 

Entheogen is currently advancing compound delivery by moderation of the pharmacokinetics to have a superior pharmacodynamic response or the effect of a compound on the body and the kinetics of absorption, distribution, metabolism and excretion.